Tag: ISR

Blue Horseshoe Stocks: Recap of Yesterday’s Huge Session

Our first order of business today will be to go over the wealth of premium gain opportunities contained in yesterday’s premarket report. We had not one, but three of our selections make major moves, not to mention a couple of other modest gainers.

Prima BioMed, Ltd. PBMD

Quickly shooting to the top of our watchlist was PBMD. Its performance was exhilarating to behold as the stock went on an absolute tear from a low of 2.08 on up to 6.48. It marked an epic intraday run which produced total possible gains on the order of 211%

The move occurred on monstrous volume to the tune of nearly 62X the 3-month average, and stemmed largely from some positive results on one of the company’s trial drugs, announced Tuesday. >> READ PR

With the kind of momentum we’ve witnessed building up in just a single session from PBMD, we’re very interested to continue to follow the price action. A significant dip-and-rip scenario could soon present itself.

IsoRay, Inc. ISR

We also tagged ISR in yesterday’s extended watchlist, and it too shot up rapidly with the help of optimistic results from one of its own drug trials. From an early low of 1.86, the stock ran up as high as 3.38, carving out an intraday rip of 82%

This morning, we saw ISR go as high as 4.00 in premarket trading, extending the overnight range on this play to an eyebrow-raising 115%

We’ll certainly be monitoring this stock as we cruise into week’s end. Like PBMD, we’ll be on the lookout for profit-taking to possibly put a dip-and-rip scenario into effect.

Holiday Island Holdings, Inc. HIHI

In our closing thought from yesterday’s report, we called attention to a massive one-third share reduction being enacted by HIHI, and were extremely pleased to have done so. From a low of .0015, the stock broke out to hit .00265; a healthy move totaling 76%

We then saw it pull back into the close, but we’re not finished monitoring the stock by any means. We caught wind of a promotion (in which we are not involved) going out on HIHI this morning, which could provide us with an impeccably-timed boost to extend our profits as we look to take them off the table.

In light of the monumental performances we’ve seen out of news-fueled pharma plays this week, we’ve dug up a few more this morning for us to pin to our watchlists:

Calithera Biosciences, Inc. CALA

Actinium Pharmaceuticals, Inc. ATNM

Ampio Pharmaceuticals, Inc. AMPE

Extended Watchlist:
NSPR, CTP, AVEO

Blue Horseshoe Stocks: PZOO News & Other Updates

Pazoo, Inc. PZOO

We directed our attention at PZOO to start off the week, and so far the stock has put on a good performance. From a low of a penny on Monday we saw a nice move up, and yesterday the stock continued to build a higher base of support.

We witnessed a trading range from .0131 to .0144, a modest 10% intraday move; from our observed low on Monday, that’s registered as a nice 44% intraweek swing.

We’re going to need to keep our eye on PZOO as the week progresses, especially in light of the important news update we received from the company this morning regarding its ongoing expansion into the marijuana testing business (excerpt below).

WHIPPANY, N.J., May 20, 2015 (GLOBE NEWSWIRE) — Pazoo, Inc. (OTC:PZOO), is pleased to announce that wholly-owned subsidiary Harris Lee has gained the exclusive right to operate testing laboratories in the State of Colorado utilizing Steep Hill Labs’ highly-rated testing techniques and methodology.

Colorado is the third state in which Pazoo Inc. subsidiaries have created a license relationship with Steep Hill for their testing technology. Agreements have been established with Steep Hill in Nevada, Oregon and now Colorado. >> FULL PR

PlasmaTech Biopharmaceuticals, Inc. PTBI

PTBI is another call we made on Monday which has also returned a noteworthy two-day performance. It’s one that we had already tracked  over an impressive range earlier this month, and when we rehashed it on Monday, we observed a low of 8.05.

Yesterday the stock pushed its way to a high of 10.83, marking a 35% swing. We want to continue to keep a keen eye on PTBI; this morning’s PR alludes to the granting of Orphan Drug status to a couple of the company’s products by the FDA:

NOHO, Inc. DRNK

DRNK also appeared in yesterday’s premarket report, and we wanted to mention the activity that ensued. After gapping up in the morning, the stock executed a dip-and-rip pattern, coming down to bounce off of a low of .0054 before running back to .0076, providing a chance at up to 41% in intraday gains.

Enviro-Serv, Inc. EVSV

We mentioned EVSV along with MNKD yesterday, and it too made a strong move on the day. From .001 the stock found a subsequent high of .0015 for a nice, round, 50% pop.

Side Note:

We’re going to have an eye on HIHI as well today on the heel of some share reduction news. The company is reducing the outstanding shares by nearly a third, so we’ll be interested to follow the resulting price action. >> VIEW PR

Extended Watchlist:
PBMD, ISR, GNCA, PBY, AVEO

Blue Horseshoe Stocks: CYBR, MCP, MEIP & More

CyberArk Software, Ltd. CYBR

Our first experiences with CYBR were good ones, when we successfully called a couple of potentially lucrative options trades around the middle of last month. It was in our report from February 13ththat we targeted CYBR $50 and $55 Calls, and that day we saw moves in those contracts of 72% and 165% respectively.
–
We flagged CYBR once again yesterday, which had previously been under several weeks of consolidation, yet was gapping up in the premarket. The stock did well in reversing its path, trading in a range from 50.79-55.03, and holding the majority of those gains into the close.

Our current options idea is going to be the 04/17 $50 Calls (Closed at 6.60 yesterday). Should CYBR reach its way back to the $60-level anytime in the next few weeks, the gains we see in those contracts will be quite substantial.

Molycorp, Inc. MCP

MCP appeared in yesterday’s extended watchlist and demonstrated a reversal of its own. We’re going to place MCP on more intensive watch as the week progresses, as it has the markings of a potential bottom play.

We’ve illustrated some of the key characteristics of the chart below, which appears to be gearing up for what could be a big swing. The stock ran well over a dollar at the beginning of last month, so the potential for rapid gains has certainly been demonstrated.

MEI Pharma, Inc. MEIP

We’ve also got an eye on MEIP after the stock was crushed down to a 52-week low yesterday, following the company’s announcement of the failure of its cancer drug in middle-stage testing.

A single-session depreciation on the order of 70% is the hallmark of one heck of a knee-jerk reaction, and the stock appears to be gapping up slightly this morning, so we’ll be on the lookout for a recovery in MEIP shares in coming days.

Extended Watchlist:
IMGN, ATOS ISR, HEB, GEVO, NEPT

Blue Horseshoe Stocks: Mid-Week Review

Direxion Daily Jr Gld Mnrs Bear 3X ETF (JDST)

Yesterday marked the third consecutive day that we had been tracking the JDST ETF, and the third consecutive session that we witnessed a northerly move. From an early low of 14.07, it would go on to attain a daily high of 17.42 on volume that exceeded the 3-month average by nearly 2M shares. That worked out to a solid intraday run of 24%

As measured from the low we observed following our initial alert on Friday morning (11.40) to yesterday’s peak PPS, the JDST has risen 53% overall.

As we’ve previously mentioned, due to the nature of the fund, extended success for the JDST is contingent upon continued hardship for gold, which continued to flirt with its 3-month lows yesterday.

Side Note:

By now, our regular readers are aware of our trading chatrooms*, which have have turned up prime opportunities in the past due to reader participation. Yesterday, we were treated to an excellent idea from ‘Tango’ in the form of PPCH:

Following this exchange, PPCH traded in a monstrous range from .006-.035, a 483% intraday rip!

Incidentally the company also has news out this morning:

MELBOURNE, Australia, March 11, 2015 /PRNewswire/ — Propanc Health Group Corporation (PPCH) (“Propanc” or “the Company”), an emerging healthcare company focusing on the development of new and proprietary treatments for cancer patients, today announced fresh new insights have emerged into the development and spread of carcinomas >> FULL PR

*Remember, any readers who’d like to get involved in our trading chats in the future can do so easily! For either the Premium or the free chats, simply add “stocksumo” as a contact on Skype and request access!

Extended Watchlist:
BLRX, ARCP, CYTX, ISR

Blue Horseshoe Stocks: MDCN Refocus & More

Pervasip Corp. PVSP

To kick off this short week we’d like to take note of PVSP, a super-subpenny stock that has recently awoken from the dead and begun to show some vigorous swings on the chart. PVSP has been bouncing around in a rough channel between .0002 and .0004 for the past couple of weeks.

Every so often we like to watch super-subpennies like this one for the low-risk-high-reward factor; with little room to fall, the rock bottom prices represent a true ground-floor opportunity. Many times in the past have we caught on with a play in this situation and reaped the benefit of rapid and monstrous upswings. We’ll keep a close eye on PVSP for the possible chance to do it again.

Last week the company announced that it had completed deal that will allow it to write approximately $2M off of its existing debt for an up-front sum of just $100K, and a later payment of $25K in October. >>> VIEW PR 

Medican Enterprises, Inc. MDCN

MDCN is a marijuana-related stock that we’ve had on our long term radar for quite some time. Toward the beginning of the year we re-tagged the stock for monitoring and today seems like a good time to focus in more intently on a couple of key points that seem to indicate a possible opportunity ahead.

In addition to a recent property acquisition with potentially exciting implications (PR excerpt below), we’re catching MDCN off of its 52-week low which was just realized on Thursday. Our regular readers are well aware of how fond we are of stocks coming up off of their annual lows. We’ve successfully navigated countless plays in this exact situation, and in many cases have come up with major gains for our efforts.

LAS VEGAS–(BUSINESS WIRE)–Medican Enterprises Inc. (MDCN), a company seeking promising pharmaceutical and other business opportunities in the emerging medical and recreational marijuana sector, announced that it has entered into a purchase agreement to acquire a 7,200 square foot retail and commercial property in Phoenix, Arizona.

The property is currently leased through August 2018 to an Arizona state licensed medical marijuana dispensary. Per the purchase agreement, the lease agreement will be assigned to Medican. >> FULL PR

Extended Watchlist:
CYTR, ISR, AUY, EHTH, SWHC, FRO, IBIO

Get Our FREE Daily Reports!

SUBSCRIBE